Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif. , March 21, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March

Preclinical data builds on objective tumor responses achieved in the ongoing Phase 1/1b clinical trial of CPI-818 for the treatment of refractory T cell lymphoma and further supports its broad potential across a range of oncology and immune diseases BURLINGAME, Calif.

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing re-emergence of the virus Data to be presented at the Conference on Retroviruses and Opportunistic Infections Research partners from UCSF and Vitalant to continue studying potential for ITK